Indications: Olaparib is prescribed for several cancer types, including ovarian, breast, and pancreatic cancers, under specific conditions such as recurrence or mutations like BRCA mutations.

Pharmacology: Olaparib operates by hindering PARP enzymes, pivotal in cell DNA repair. This inhibition impairs cancer cells’ ability to mend their DNA, resulting in cell death.

Dosage and Administration: Typically, Olaparib is taken orally in 300 mg doses twice daily, with or without food. Adjustments might be necessary based on individual patient responses and side effects.

Interactions: Olaparib can interact with various medications, necessitating patients to disclose their entire medication list to healthcare providers, including prescriptions, over-the-counter drugs, supplements, and vitamins.

Side Effects: Common side effects encompass nausea, vomiting, fatigue, anemia, reduced appetite, diarrhea, and abdominal discomfort. Serious effects may include bone marrow suppression and heightened risk of specific cancers.

Precautions and Warnings: Olaparib usage may result in bone marrow suppression, prompting regular blood tests for monitoring blood cell counts. Additionally, patients should be monitored for potential new cancer developments.

Overdose Effects: In instances of overdose, supportive measures are employed as there’s no specific antidote. Treatment focuses on alleviating symptoms and providing supportive care.